Humulin M3 Kwikpen (Mixture 3)

Humulin M3 Kwikpen (Mixture 3) is a prefilled insulin pen containing insulin human (rDNA) at a concentration of 100 U/mL, formulated as a fixed 30 % NPH and 70 % regular insulin mixture. It is supplied as a solution for subcutaneous injection and is marketed in the European Union as a prescription‑only product for diabetes management. The pen device delivers precise doses, facilitating flexible insulin therapy for both type 1 and type 2 diabetes patients.

Humulin M3 Kwikpen is indicated for the control of blood glucose in adults with diabetes when a mixed insulin regimen is appropriate.

- Basal‑bolus therapy in type 1 diabetes requiring both rapid‑acting and intermediate‑acting insulin. - Supplemental insulin for type 2 diabetes patients who cannot achieve targets with oral agents alone. - Transition from separate NPH and regular insulin injections to a single convenient device. - Use in hospital or outpatient settings where subcutaneous insulin administration is required. - Adjusted dosing for patients with variable meal patterns or physical activity levels. - Suitable for patients who prefer a prefilled pen over vial‑and‑syringe delivery.

Like all insulin preparations, Humulin M3 may cause adverse reactions at the injection site or systemic level.

Common: - Hypoglycemia, especially if meals are missed or dose is excessive. - Injection‑site redness, swelling, or itching. - Lipodystrophy presenting as localized thickening or thinning of subcutaneous tissue. - Transient weight gain due to fluid retention.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, or loss of consciousness. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Persistent edema or worsening heart failure in susceptible patients. - Unexplained hypokalemia or other electrolyte disturbances.

When prescribing Humulin M3, clinicians should evaluate patient‑specific factors and monitor for conditions that could alter insulin requirements or increase risk of complications.

- Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced. - Use caution in patients with a history of severe hypoglycemia or hypoglycemia unawareness. - Review cardiovascular status; rapid glucose shifts can precipitate ischemic events. - Avoid use during pregnancy unless benefits outweigh risks; it is classified as pregnancy category B. - Monitor for signs of lipodystrophy and rotate injection sites to prevent tissue changes. - Consider reduced dosing during periods of decreased caloric intake or increased physical activity.

Humulin M3 can interact with other medications that affect glucose metabolism, insulin sensitivity, or absorption.

Avoid: - Adding other rapid‑acting insulins without dose reduction, which may cause severe hypoglycemia. - Combining full‑dose sulfonylureas with Humulin M3, increasing hypoglycemia risk.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Corticosteroids, which raise glucose and may require higher insulin doses. - Thiazide diuretics, which can reduce insulin sensitivity. - ACE inhibitors or ARBs, which may enhance insulin’s glucose‑lowering effect. - Alcohol, especially binge drinking, which can cause unpredictable glucose changes.